PT863760E - Utilizacao de compostos antimineralocorticoides contra a sindroma de privacao de narcoticos - Google Patents

Utilizacao de compostos antimineralocorticoides contra a sindroma de privacao de narcoticos

Info

Publication number
PT863760E
PT863760E PT96931876T PT96931876T PT863760E PT 863760 E PT863760 E PT 863760E PT 96931876 T PT96931876 T PT 96931876T PT 96931876 T PT96931876 T PT 96931876T PT 863760 E PT863760 E PT 863760E
Authority
PT
Portugal
Prior art keywords
narcotics
privacy
syndrome
utilization
compounds against
Prior art date
Application number
PT96931876T
Other languages
English (en)
Inventor
Francis Petit
Daniel Philibert
Nick Goeders
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT863760E publication Critical patent/PT863760E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PT96931876T 1995-09-21 1996-09-19 Utilizacao de compostos antimineralocorticoides contra a sindroma de privacao de narcoticos PT863760E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9511086A FR2739029B1 (fr) 1995-09-21 1995-09-21 Nouvelle application therapeutique des composes antimineralo-corticoides

Publications (1)

Publication Number Publication Date
PT863760E true PT863760E (pt) 2002-05-31

Family

ID=9482793

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96931876T PT863760E (pt) 1995-09-21 1996-09-19 Utilizacao de compostos antimineralocorticoides contra a sindroma de privacao de narcoticos

Country Status (10)

Country Link
US (3) US6147066A (pt)
EP (1) EP0863760B1 (pt)
JP (1) JP2000513704A (pt)
AT (1) ATE209920T1 (pt)
DE (1) DE69617729T2 (pt)
DK (1) DK0863760T3 (pt)
ES (1) ES2166001T3 (pt)
FR (1) FR2739029B1 (pt)
PT (1) PT863760E (pt)
WO (1) WO1997010827A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518509A (ja) 1997-10-06 2001-10-16 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ グルココルチコイド関連機能不全に関連した精神病の処置のための方法。
EP1726307A3 (en) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CA2478172A1 (en) * 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
US8139039B2 (en) * 2007-07-31 2012-03-20 Kent Displays, Incorporated Selectively erasable electronic writing tablet
US8228301B2 (en) * 2007-07-31 2012-07-24 Kent Displays Incorporated Multiple color writing tablet
US7960368B2 (en) * 2008-03-05 2011-06-14 Everstra, Inc. Bismethylene-17A carbolactones and related uses
KR101396373B1 (ko) * 2009-05-28 2014-05-19 켄트 디스플레이스 인코포레이티드 쓰기용 태블릿 정보 기록 장치
US9134561B2 (en) 2011-11-01 2015-09-15 Kent Displays Incorporated Writing tablet information recording device
US9116379B2 (en) 2012-05-22 2015-08-25 Kent Displays Incorporated Electronic display with semitransparent back layer
US9235075B2 (en) 2012-05-22 2016-01-12 Kent Displays Incorporated Electronic display with patterned layer
US10088701B2 (en) 2013-11-01 2018-10-02 Kent Displays Inc. Electronic writing device with dot pattern recognition system
US9851612B2 (en) 2014-04-02 2017-12-26 Kent Displays Inc. Liquid crystal display with identifiers
TWI646971B (zh) * 2015-12-04 2019-01-11 鄭恩哲 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用
RU2019126483A (ru) 2017-01-23 2021-02-24 Ридженерон Фармасьютикалз, Инк. Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
EP3610029A1 (en) * 2017-04-11 2020-02-19 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
CN111183234A (zh) 2017-10-11 2020-05-19 雷杰纳荣制药公司 在表达pnpla3 i148m变异的患者的肝病治疗中对hsd17b13的抑制

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533517A1 (en) * 1991-08-20 1993-03-24 Chiba Flour Milling Co. Ltd. LPS-containing anti-withdrawal agents
US5869474A (en) * 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal

Also Published As

Publication number Publication date
WO1997010827A1 (fr) 1997-03-27
DE69617729T2 (de) 2002-08-08
FR2739029B1 (fr) 1997-11-21
EP0863760A1 (fr) 1998-09-16
EP0863760B1 (fr) 2001-12-05
US6147066A (en) 2000-11-14
ATE209920T1 (de) 2001-12-15
DK0863760T3 (da) 2002-04-02
FR2739029A1 (fr) 1997-03-28
JP2000513704A (ja) 2000-10-17
DE69617729D1 (de) 2002-01-17
US20040242552A1 (en) 2004-12-02
ES2166001T3 (es) 2002-04-01
US6759399B1 (en) 2004-07-06

Similar Documents

Publication Publication Date Title
PT863760E (pt) Utilizacao de compostos antimineralocorticoides contra a sindroma de privacao de narcoticos
PT880350E (pt) Tratamento de esclerose multipla
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
EP0831832A4 (en) METHODS FOR CONTROLLING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES
ATE409486T1 (de) Behandlung hyperproliferativer erkrankungen
EA200101089A1 (ru) Новый способ лечения
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
IL134430A0 (en) Use of cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
DK1003494T3 (da) (d)-metadon, et ikke-opioidt analgetikum
ATE304364T1 (de) Chromium/biotin behandlung von typ-ii diabetes
EA199800139A1 (ru) Способ лечения аденомы толстой кишки
EA200100716A1 (ru) Способ профилактики рака молочной железы
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
EA199800866A1 (ru) Способ снятия боли
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DK0754054T3 (da) Antirestenosis-protein
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
EA199800535A1 (ru) Способ лечения боли
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
DE69831959D1 (de) Verwendung von (E)-metanicotinederivate als Analgetika
MY118982A (en) Method of reducing tissue damage associated with ischemia
PL328949A1 (en) Method of treatng excessive aggression
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.